For families facing hemolytic disease of the fetus and newborn (HDFN), few treatments are as critical as intrauterine transfusions (IUTs). These procedures, in which donor red blood cells are transfused directly into the fetus’s circulation, can stabilize anemia caused by maternal antibodies attacking fetal red blood cells.
But as delivery draws near, an important question arises: when exactly should IUTs be stopped?
Weighing the risks of treatment versus early delivery
Deciding when to stop IUTs requires balancing the risks of continuing the treatment versus the risks of delivering a premature baby. Each transfusion carries potential complications, such as infection, preterm labor or injury to the fetus. But on the other hand, stopping too early can leave the baby dangerously anemic.
Learn more about HDFN treatment and care
Doctors weigh several key factors, including the gestational age of the fetus, how stable the baby has been after previous transfusions, the presence of hydrops fetalis (a severe complication where fluid builds up in fetal tissues) and the mother’s antibody levels. The goal is always to get the pregnancy as close to term as possible, while minimizing risk to both baby and mother.
What is hydrops fetalis?
Hydrops fetalis is a symptom of an underlying medical condition that affects an unborn baby and can occur with HDFN. In this condition, large amounts of fluid accumulate in the baby’s tissues or organs. If it remains untreated, this abundance of fluid can place stress on the fetal heart and other vital organs.
Considering gestational age
Gestational age is often the primary guide. In the early and mid-second trimester, the benefits of continuing transfusions far outweigh the risks of preterm delivery.
However, once the pregnancy reaches 35 weeks, the equation shifts. At that point, most babies can be safely delivered and treated outside the womb with neonatal transfusions, phototherapy and, if needed, exchange transfusions.
Making individualized decisions
No two pregnancies with HDFN are exactly alike, so decisions around stopping IUTs are highly individualized. For example, if a fetus has tolerated transfusions well, and the medical team is confident in close monitoring, doctors may decide to continue treatments and push the pregnancy closer to 37 weeks before delivery.
Conversely, if there’s complications like hydrops before 35 weeks, doctors may opt to stop IUTs earlier and plan for neonatal intensive care after birth.
Ultimately, stopping IUTs is not a single physician’s call, but the result of collaboration among maternal-fetal medicine specialists, neonatologists and transfusion medicine experts. Parents also play a central role in the decision-making process, as doctors weigh medical risks alongside family preferences and concerns.
Sign up here to get the latest news, perspectives, and information about HDFN sent directly to your inbox. Registration is free and only takes a minute.
